APOH and COVID-19: Since anti-β2-GPI antibodies are the main candidate to trigger platelet activation, platelets from healthy donors were treated with Ig fractions isolated from patients with AIS during COVID-19, with Ig fractions from healthy donors or with polyclonal anti-β2-GPI IgG.